Thrombosis in conversation

Dr Larry Jackson and Dr Barnes consider how best to tackle a patient case study with a focus on optimal management of AF in older patients at high risk of bleeding.

Dr Barnes and Dr Frederik Verbrugge take a closer look at the management of stroke risk in people with AF and comorbid conditions.

“There’s no doubt that pharmacological prophylaxis is under used.” Dr Carrier and Dr Barnes discuss the real-world evidence underpinning strategy for the management of CAT.

Dr Marc Carrier and Dr Barnes discuss the challenges posed by cancer heterogeneity when managing CAT.

Dr Proietti and Professor Lip highlight unmet needs in AF management for stroke prevention and their prevalence among people with AF.

Can real-world evidence improve treatment selection and individualised care for AF in stroke prevention? Dr Proietti and Professor Lip discuss.

“Wearable technologies for stroke prevention are an exciting trend in the field” Dr Proietti and Professor Lip examine the benefits and disadvantages of wearable technologies for AF screening and detection in stroke prevention.

Dr Rajasekhar and Dr Barnes consider treatment selection for CAT, highlighting the role of warfarin, and discuss optimal treatment length and the use of IVC filters according to current guidelines.

“Why did a patient get their blood clot in the first place, and how does that influence our decisions?” Dr Barnes is joined by Dr Anita Rajasekhar for a discussion of the causes and risk factors of VTE in people without cancer, and the relationship of risk and cause with treatment selection. With reference to clinical guidance, Dr Rajasekhar talks about diagnosis of recurrent VTE in the clinical setting and the importance of patient preference.

Dr Deborah Siegal and Dr Barnes discuss thrombocytopenia and its treatment, including anticoagulation therapy and the inferior vena cava (IVC) filter, and touch on the challenge of balancing bleeding risk with VTE recurrence in people with brain tumours.